Refinements in the use of Liquid Biopsy to Guide Tumour Management for Advanced Breast Cancer – ESMO
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Two studies presented at ESMOBreast25 highlight refinements in the use of Liquid Biopsy to guide tumour management for advanced Breast Cancer.
A secondary analysis of the PADA-1 phase III Clinical Trial reported a defined window for ESR1 mutation detection. The incidence over time of ESR1mut was uneven, with lower detection before 6 months and after 30 months in HR+/HER2– metastatic Breast Cancer.
A retrospective analysis of the I-SPY 2 phase II Clinical Trial investigating individualised treatment strategies based on molecular characteristics, demonstrated that high ctDNA levels pre-neoadjuvant therapy predicted metastatic recurrence in high-risk early Breast Cancer (HR+, HER2+ and TNBC).
Read the commentary on these findings in the ESMO Daily Reporter.”
ESMO presented findings from ESMOBreast25 emphasizing liquid biopsy’s evolving role in breast cancer. The PADA-1 analysis identified optimal ESR1 mutation detection windows, while I-SPY 2 showed ctDNA levels as predictors of recurrence risk pre-treatment in high-risk early breast cancer.
More posts featuring European Society for Medical Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023